Ortho Clinical Diagnostics Holdings PLC Stock News

Ortho Clinical Diagnostics Holdings PLC (NASDAQ:OCDX ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Bryan Brokmeier - Vice President, Investor Relations Chris Smith - C

Ortho Clinical (OCDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

OCDX vs. DOCS: Which Stock Is the Better Value Option?

Ortho Clinical (OCDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

ASRT, CPRI, GRIN, OCDX, and KN have been added to the Zacks Rank #1 (Strong Buy) List on March 24, 2022.

OCDX vs. PGNY: Which Stock Is the Better Value Option?

Ortho Clinical (OCDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

CIVI, CLW, OCDX, WCC, and DBI have been added to the Zacks Rank #1 (Strong Buy) List on February 18, 2022.

CIVI, DBI, and OCDX made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 18, 2022

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and year ended December 31, 2021. Fourth Quarter 2021 Highlights Signed definitive agreement to acquire Ortho Clinical Diagnostics Holdings plc ("Ortho"), funded through a combination of cash and newly issued shares in the combined company. Total revenue was $636.

Upgrades HSBC upgraded the previous rating for Equinor ASA (NYSE: EQNR ) from Hold to Buy. For the fourth quarter, Equinor had an EPS of $1.35, compared to year-ago quarter EPS of $0.17. The current stock performance of Equinor shows a 52-week-high of $32.16 and a 52-week-low of $17.78. Moreover, at the end of the last trading period, the closing price was at $29.45. Argus Research upgraded the previous rating for Canadian National Railway Co (NYSE: CNI ) from Hold to Buy. For the fourth quarter, Canadian National Railway had an EPS of $1.36, compared to year-ago quarter EPS of $1.10. The current stock performance of Canadian National Railway shows a 52-week-high of $136.22 and a 52-week-low of $100.66. Moreover, at the end of the last trading period, the closing price was at $126.93. According to TD Securities, the prior rating for Equinix Inc (NASDAQ: EQIX ) was changed from Hold to Buy. For the fourth quarter, Equinix had an EPS of $6.22, compared to year-ago quarter EPS of $5.76. At the moment, the stock has a 52-week-high of $885.26 and a 52-week-low of $586.73.

Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX ) reported Q4 sales of $521 million , almost in line with the consensus of $521.17 million. The sales increased 0.8% on a reported basis, +1.6% on constant currency, and excluding CoV-2 assays, sales increased 5.0%. Core Revenue increased 3.5% to $518.9 million, up … Full story available on Benzinga.com

OCDX earnings call for the period ending December 31, 2021.